J. Gandy

OverviewAI-generated summary

J. Gandy's research group focuses on the formulation of drug delivery systems, particularly liposomes, for targeted therapeutic applications. Recent work has investigated liposome formulations designed for tumor-targeted drug delivery in conjunction with radiation therapy. This research aims to enhance the efficacy of cancer treatments by concentrating therapeutic agents at the tumor site.

In addition to drug delivery, Gandy has also been active in public health research concerning infectious diseases and vaccine uptake. Studies have examined COVID-19 vaccine hesitancy and uptake among students at public higher education institutions in Arkansas. Further research has explored SARS-CoV-2 antibody seroprevalence and associated mitigation behaviors among college students, providing insights into the dynamics of viral spread and public health responses within university settings.

Gandy holds the designation of a high-impact researcher, evidenced by an h-index of 20 and over 1,600 citations across 76 publications. Key collaborators include Robert J. Griffin, Amanda J. Stolarz, and Azemat Jamshidi‐Parsian from the University of Arkansas for Medical Sciences, as well as Bijay P. Chhetri from the University of Arkansas at Little Rock.

Metrics

• h-index: 20
• Publications: 76
• Citations: 1,628